Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder [Yahoo! Finance]
Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $8.00 price target on the stock.
Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update